Advertisement

Despite Recent Speed Bumps, Biogen's Stock Will Soon Grow Again

Despite Recent Speed Bumps, Biogen's Stock Will Soon Grow Again

Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors to be skeptical. Indeed, investing in Biogen in 2016 and selling today would have meant a loss of 16.6%.